Primary Progesterone Therapy for Operable Breast Cancer

• Status: Completed
• Trial end date: 2020-05-29
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to test the effect of primary progesterone on overall and disease free survival in women with operable breast cancer. The study addresses two issues related to breast cancer surgery:

• Circulating progesterone at the time of surgery might counteract the detrimental effect of estrogen on survival of women with operable breast cancer.

• Events at the time of surgery may have an impact on the natural history of breast cancer

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tata Memorial Hospital
• Collaborator: Ministry of Science and Technology, India
• Treatments: 11-hydroxyprogesterone; 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-hydroxy-progesterone caproate; Progesterone

Criteria

Inclusion Criteria:

• Unilateral operable palpable breast cancer

Exclusion Criteria:

• Previous history of excision biopsy of the primary tumour

• History of other epithelial/mesenchymal malignant tumours except basal cell carcinoma/squamous cell carcinoma (BCC/SCC) of skin